A report from the phase II WIN trial, in which HLA-A2-positive CML and AML patients were vaccinated with two DNA vaccines containing either the WT1-37 or WT1-126 epitope, showed similar results. The gene discussed is WT1; the disease is acute myeloid leukemia.